__NUXT_JSONP__("/drugs/Nifurtimox", (function(a,b){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:"LAMPIT",indication:"1 INDICATIONS AND USAGE LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi . This indication is approved under accelerated approval based on the number of treated patients who became immunoglobulin G (IgG) antibody negative or who showed an at least 20% decrease in optical density on two different IgG antibody tests against antigens of T. cruzi . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) [see Clinical Studies ( 14 )]. LAMPIT is a nitrofuran antiprotozoal, indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi . This indication is approved under accelerated approval based on the number of treated patients who became immunoglobulin G (IgG) antibody negative or who showed an at least 20% decrease in optical density on two different IgG antibody tests against antigens of T. cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 , 14 )",manufacturer:"Bayer Healthcare Pharmaceuticals INC.",splSetId:"90d09714-a8b1-4696-8ada-f99dc54d0721"}],id:a,nciThesaurus:{casRegistry:"23256-30-6",chebiId:"",chemicalFormula:"C10H13N3O5S",definition:"A nitrofuran derivative with antiprotozoal and potential antineoplastic activities. Nifurtimox is reduced by cytosol enzymes or flavin-containing microsomal enzymes to a highly reactive nitro anion free radical; autooxidation of the nitro anion free radical generates cytotoxic superoxide anion (02-). In addition, nifurtimox-derived nitro anion free radicals may alkylate macromolecules such as nucleic acids and proteins, resulting in the disruption of their structure and function.",fdaUniiCode:"M84I3K7C2O",identifier:"C71734",preferredName:a,semanticType:"Pharmacologic Substance",subclassOf:["C277"],synonyms:["4-((5-Nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide","BAY 2502","BAYER 2502","Lampit","NIFURTIMOX",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FNifurtimox",extension:".json",createdAt:b,updatedAt:b}}],fetch:{},mutations:void 0}}("Nifurtimox","2021-10-30T13:43:50.153Z")));